Juliana Di Iulio

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

Constantine S. Tam, Mary Ann Anderson, Christiane Pott et al. · New England Journal of Medicine · 2018 · 429 citations

Medicine, Pharmacology, Pharmacotherapy +13

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

Harry Iland, Ken Bradstock, Shane G. Supple et al. · Blood · 2012 · 340 citations · Full text

Medicine, Hematology, Oncology +15

Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial

Bryan Burmeister, Michael A. Henderson, Jill Ainslie et al. · The Lancet Oncology · 2012 · 293 citations

Medicine, Oncology, Surgery +17

Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial

Michael A. Henderson, Bryan Burmeister, Jill Ainslie et al. · The Lancet Oncology · 2015 · 224 citations

Medicine, Oncology, Surgery +14

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial

Harry Iland, Marnie Collins, Ken Bradstock et al. · The Lancet Haematology · 2015 · 170 citations

Medicine, Hematology, Oncology +10